36466 Federal Register / Vol. 65, No. 111 / Thursday, June 8, 2000 / Notices

DEPARTMENT OF JUSTICE

Notice of Lodging of Consent Decree

Pursuant to the Comprehensive

Environmental Response,

Compensation, and Liability Act of

1980, as Amended

Notice is hereby given that a proposed

consent decree in the action entitled

United States v. Holden, et. al., Civil

Action No. 00CV11036EFH (D. Mass.),

was lodged on May 26, 2000, with the

United States District Court for the

District of Massachusetts. The proposed

consent decree resolves the claims of

the United States claims against several

potentially responsible parties (‘‘Settling

Defendants’’) at the Nyanza Chemical

Waste Dump Superfund Site, located in

Ashland, Massachusetts (‘‘Site’’), under

the Comprehensive Environmental

Response, Compensation, and Liability

Act (‘‘CERCLA’’), 42 U.S.C. 9601 et seq.

The consent decree will also resolve the

claims of the Commonwealth of

Massachusetts (‘‘Commonwealth’’) in

connection with the Site under CERCLA

and the Massachusetts Oil and

Hazardous Material Release Prevention

and Response Act, M.G.L. c. 21E. The

Settling Defendants include Nelson W.

Holden, as Trustee of the Holden–

Ashland Trust, Martha E. Holden, as

Trustee of the Holden–Ashland Trust,

and William M. Leacu. The

Environmental Protection Agency has

determined that the Settling Defendants

qualify for a de mimimis settlement

under section 122(g)(1)(B) of CERCLA,

42 U.S.C. 9622(g)(1)(B). The consent

decree includes a covenant not to sue by

the United States under sections 106

and 107 of CERCLA, 42 U.S.C. 9606 and

9607 (including claims for natural

resources damages), and under Section

7003 of the Resource Conservation and

Recovery Act (‘‘RCRA’’), 42 U.S.C. 6973.

Under the proposed consent decree,

the Settling Defendants have agreed to

record an Environmental Restriction

and Easement (‘‘Easement’’) with

respect to each of their properties

located at the Site. The Easements will

impose certain restrictions on the use of

these properties and will also provide

access rights to the United States (until

completion of the remedial action at the

Site) and to the Commonwealth (after

completion of the remedial action at the

Site).

The Department of Justice will

receive, for a period of up to thirty days

from the date of this publication,

comments relating to the proposed

consent decree. Any comments should

be addressed to the Assistant Attorney

General for the Environment and

Natural Resources Division, P.O. box

7611, Ben Franklin Station, Washington

DC 20044, and should refer to United

States v. Holden, et al., DOJ Ref.

Number 90–11–2–340C. Commenters

may request an opportunity for a public

meeting in the affected area, in

accordance with Section 7003(d) of

RCRA, 42 U.S.C. 6973(d).

The proposed consent decree may be

examined at EPA Region 1, located at

One Congress Street, Suite 1100, Boston,

MA 02114 (contact Peter DeCambre,

617–918–1890). A copy of the proposed

consent decree may be obtained by mail

from the Department of Justice Consent

Decree Library, P.O. Box 7611,

Washington, DC 20044. In requesting a

copy, please refer to the referenced case

and enclose a check in the amount of

$23.75 (25 cents per page reproduction

costs).

Joel M. Gross,

Section Chief, Environmental Enforcement

Section, Environment and Natural Resources

Division.

[FR Doc. 00–14456 Filed 6–7–00; 8:45 am]

BILLING CODE 4410–15–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Registration

By Notice dated February 10, 2000,

and published in the Federal Register

on February 17, 2000, (65 FR 33) Ganes

Chemicals Inc., Industrial Park Road,

Pennsville, New Jersey 08070, made

application by renewal to the Drug

Enforcement Administration (DEA) to

be registered as a bulk manufacturer of

the basic classes of controlled

substances listed below:

Drug Schedule

Methylphenidate (1724) ............. II

Amobarbital (2125) .................... II

Pentobarbital (2270) .................. II

Secobarbital (2315) ................... II

Glutethimide (2550) ................... II

Methadone (9250) ..................... II

Methadone-intermediate (9254) II

Dextropopoxyphene, bulk (nondosage forms) (9273).II

The firm plans to manufacture the

listed controlled substances for

distribution as bulk products to its

customers.

DEA has considered the factors in

Title 21, United States Code, Section

823(a) and determined that the

registration of Ganes Chemicals, Inc. to

manufacture the listed controlled

substances is consistent with the public

interest at this time. DEA has

investigated Ganes Chemicals, Inc. on a

regular basis to ensure that the

company’s continued registration is

consistent with the public interest.

These investigations have included

inspection and testing of the company’s

physical security systems, audits of the

company’s records, verification of the

company’s compliance with state and

local laws, and a review of the

company’s background and history.

Therefore, pursuant to 21 U.S.C. 823

and 28 CFR 0.100 and 0.104, the Deputy

Assistant Administrator, Office of

Diversion Control, hereby orders that

the application submitted by the above

firm for registration as a bulk

manufacturer of the basic classes of

controlled substances listed above is

granted.

Dated: May 25, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–14478 Filed 6–7–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Registration

By Notice dated May 12, 1999, and

published in the Federal Register on

May 25, 1999, (64 FR 28214), Noramco,

Inc., 1400 Olympic Drive, Athens,

Georgia 30601, made application to the

Drug Enforcement Administration

(DEA) for registration as a bulk

manufacturer of the basic classes of

controlled substances listed below:

Drug Schedule

Codeine (9050) .......................... II

Oxycodone (9143) ..................... II

Hydrocodone (9193) .................. II

Morphine (9300) ........................ II

Thebaine (9333) ........................ II

The firm plans to support its other

manufacturing facility with

manufacturing and analytical testing.

No comments or objections have been

received. DEA has considered the

factors in Title 21, United States Code,

Section 823(a) and determined that the

registration of Noramco, Inc. to

manufacture the listed controlled

substances is consistent with the public

interest at this time. DEA has

investigated Noramco, Inc. to ensure

that the company’s registration is

consistent with the public interest. The

investigations included inspection and

testing of the company’s physical